



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



## Bcl-6 (m): 293T Lysate: sc-118780

### BACKGROUND

Bcl-6, a transcriptional repressor, binds Stat recognition-like DNA elements and influences germinal center development and Th1/Th2 differentiation. Bcl-6 negatively regulates NF $\kappa$ B expression, thereby inhibiting NF $\kappa$ B-mediated cellular functions. HDAC- and silent information regulator (SIR)-2-dependent acetylation of Bcl-6 causes downregulation of activity by inhibiting the ability of Bcl-6 to recruit complexes containing histone deacetylases (HDAC). Bcl-6 is frequently deregulated in non-Hodgkin's B cell lymphomas. The human BCL6 gene has been shown to encode a protein of 706 amino acids.

### REFERENCES

1. Pasqualucci, L., et al. 2003. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. *Leuk. Lymphoma* 44: S5-S12.
2. Ree, H.J., et al. 2003. Detection of germinal center B cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B cell lymphoma of the tonsil. *Hum. Pathol.* 34: 610-616.
3. Logarajah, S., et al. 2003. Bcl-6 is expressed in breast cancer and prevents mammary epithelial differentiation. *Oncogene* 22: 5572-5578.
4. Bos, R., et al. 2003. Protein expression of B cell lymphoma gene 6 (BCL6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ). *Oncogene* 22: 8948-8951.
5. Kurosu, K., et al. 2004. Bcl-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. *J. Immunol.* 172: 7116-7122.
6. Tunyaplin, C., et al. 2004. Direct repression of PRDM1 by Bcl-6 inhibits plasmacytic differentiation. *J. Immunol.* 173: 1158-1165.
7. Ozaki, K., et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. *J. Immunol.* 173: 5361-5371.
8. Li, Z., et al. 2005. Bcl-6 negatively regulates expression of the NF $\kappa$ B1 p105/p50 subunit. *J. Immunol.* 174: 205-214.
9. Harris, M.B., et al. 2005. Repression of an interleukin-4-responsive promoter requires cooperative Bcl-6 function. *J. Biol. Chem.* 280: 13114-13121.

### CHROMOSOMAL LOCATION

Genetic locus: Bcl6 (mouse) mapping to 16 B1.

### PRODUCT

Bcl-6 (m): 293T Lysate represents a lysate of mouse Bcl-6 transfected 293T cells and is provided as 100  $\mu$ g protein in 200  $\mu$ l SDS-PAGE buffer.

### STORAGE

Store at -20 $^{\circ}$  C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.

### APPLICATIONS

Bcl-6 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive Bcl-6 antibodies. Recommended use: 10-20  $\mu$ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.